Navigation Links
Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
Date:9/19/2008

EAST NORRITON, Pa., Sept. 19 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-tissues, today announced that it was one of only three companies featured as models of venture capital-backed innovation and success at the 35th Anniversary Celebration of the National Venture Capital Association (NVCA). P. Sherrill Neff, Partner at Quaker BioVentures -- a venture capital investor in Tengion -- presented a Tengion case study at the event on Thursday, September 18, 2008 in Mountain View, California.

For this 35th Anniversary Celebration event, the NVCA invited Tengion to showcase its Autologous Organ Regeneration Platform(TM) for nearly 200 invitation-only guests, including leading venture capitalists and entrepreneurs. The presentation was followed by a panel discussion of how to best encourage technological advances and maintain a robust pipeline of venture capital-backed innovation over the next 35 years.

"We are pleased and honored that the National Venture Capital Association selected Tengion to present at this 35th Anniversary Celebration," said Steven Nichtberger, M.D., President and CEO of Tengion. "We would like to extend our thanks to Sherrill Neff and Brenda Gavin of Quaker BioVentures and all of our investors who have worked so closely with the company to support our growth and the advances of our neo-organ and neo-tissue programs. We look forward to continuing to innovate and, ultimately, bringing important medical advances to patients who need them."

The NVCA represents more than 470 venture capital firms in the United States. Founded in 1973, the NVCA's mission is to foster a greater understanding of the importance of venture capital to the U.S. economy, and support entrepreneurial activity and innovation. The organization has marked its 35th Anniversary with key news announcements and several events in 2008.

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
2. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
3. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
4. Tengion Appoints Jeff Randall to Board of Directors
5. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
7. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
8. Resverlogixs Lead Drug Featured in Key Scientific Publication
9. Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers
10. PTC124 Featured at Third Annual Congress of Myology
11. Boston Scientifics SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, ... strange place for a head lice treatment salon to set ... a Tuscan restaurant and a French bistro on E Madison ... "We aren,t just any old lice clinic, we pride ourselves ... comfortable, and release some of the stigma associated with lice. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can ... adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect ... SalivaLab , the relationship between insulin and other relevant biomarkers can be extensively ...
(Date:2/23/2017)... Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... the international society for optics and photonics , have been named Fellows of ... individual’s significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, ...
Breaking Biology Technology:
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
Breaking Biology News(10 mins):